Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

Upal Basu Roy; Anne Marie Baird; Andrew Ciupek; Jesme Fox; Eugene Manley; Kim Norris, XX; Giorgio V. Scagliotti; Heather A. Wakelee; Tetsuya Mitsudomi; Russell C. Clark; Renee Arndt; Fred R. Hirsch; Paul A. Bunn; Matthew P. Smeltzer

doi:10.1016/j.jtocrr.2021.100269

Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

Upal Basu Roy
, Anne Marie Baird
, Andrew Ciupek
, Jesme Fox
, Eugene Manley
, Kim Norris, XX
, Giorgio V. Scagliotti
, Heather A. Wakelee
, Tetsuya Mitsudomi
, Russell C. Clark
, Renee Arndt
, Fred R. Hirsch
, Paul A. Bunn
, Matthew P. Smeltzer

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Article number	100269
Journal	JTO Clinical and Research Reports
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.jtocrr.2021.100269
State	Published - Feb 2022

Access to Document

10.1016/j.jtocrr.2021.100269

Cite this

Basu Roy, U., Baird, A. M., Ciupek, A., Fox, J., Manley, E., Norris, XX, K., Scagliotti, G. V., Wakelee, H. A., Mitsudomi, T., Clark, R. C., Arndt, R., Hirsch, F. R., Bunn, P. A., & Smeltzer, M. P. (2022). Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clinical and Research Reports, 3(2), Article 100269. https://doi.org/10.1016/j.jtocrr.2021.100269

@article{191423b74bd94e5782a471d52a37f76d,

title = "Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer",

author = "\{Basu Roy\}, Upal and Baird, \{Anne Marie\} and Andrew Ciupek and Jesme Fox and Eugene Manley and \{Norris, XX\}, Kim and Scagliotti, \{Giorgio V.\} and Wakelee, \{Heather A.\} and Tetsuya Mitsudomi and Clark, \{Russell C.\} and Renee Arndt and Hirsch, \{Fred R.\} and Bunn, \{Paul A.\} and Smeltzer, \{Matthew P.\}",

note = "Funding Information: Disclosure: Dr. Roy has received institutional research funding from AstraZeneca, Eli Lilly, Merck, Blueprint Medicine, Genentech, G1 Therapeutics, Takeda, Bristol-Myers Squibb, and Janssen not related to the current project. Dr. Baird has received institutional support funding from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Merck Sharp \& Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi, and Takeda not related to the project; has served as consultant for Janssen (honorarium received by organization) and for Roche (Dublin, Ireland). Dr. Ciupek has been consultant for Novartis, GRAIL Inc., and advisory board member for Novartis, Daiichi Sankyo, AstraZeneca, and Foundation Medicine. Dr. Fox has received institutional funding from AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Eli Lilly, Merck, Takeda, and Roche not related to the project and participated in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Novartis, Debiopharm, and Takeda. Dr. Scagliotti received honoraria from AstraZeneca, Eli Lilly, Merck Sharp \& Dohme, Pfizer, Roche, Johnson \& Johnson, Takeda; consulting or advisory role for Eli Lilly, BeiGene, and AstraZeneca; received institutional research funding from Eli Lilly and Merck Sharp \& Dohme; and received travel, accommodations from Bayer, all not related to the current project. Dr. Mitsudomi received advisory/lecture fees from AstraZeneca, Novartis, Chugai, Boehringer Ingelheim, Pfizer, Roche, Merck Sharp \& Dohme, Thermo Fisher, Roche diagnostics, Bristol-Myers Squibb, Ono Pharmaceutical, Taiho, Takeda, Amgen, Johnson and Johnson, Janssen pharma, Puma, BeiGene, Bridge Biotherapeutics, Eli Lilly, Daiichi Sankyo, and Thermo Fisher; research funding from AstraZeneca, Chugai, Boehringer Ingelheim, Pfizer, Taiho, Ono Pharmaceutical, Merck Sharp \& Dohme, Daiichi Sankyo, Eli Lilly, Ethicon, and Bridge Biotherapeutics not related to this project. Dr. Bunn has received consulting income from AstraZeneca, Ascentage, Bristol-Myers Squibb, C-Stone, Imidex, Merck, and Verastem not related to this project. Dr. Smeltzer has worked as a paid research consultant for the Association of Community Cancer Centers. The remaining authors declare no conflict of interest.",

year = "2022",

month = feb,

doi = "10.1016/j.jtocrr.2021.100269",

language = "English",

volume = "3",

journal = "JTO Clinical and Research Reports",

issn = "2666-3643",

publisher = "Elsevier Inc.",

number = "2",

}

Basu Roy, U, Baird, AM, Ciupek, A, Fox, J, Manley, E, Norris, XX, K, Scagliotti, GV, Wakelee, HA, Mitsudomi, T, Clark, RC, Arndt, R, Hirsch, FR, Bunn, PA & Smeltzer, MP 2022, 'Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer', JTO Clinical and Research Reports, vol. 3, no. 2, 100269. https://doi.org/10.1016/j.jtocrr.2021.100269

TY - JOUR

T1 - Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials

T2 - Why It Matters to People With Lung Cancer

AU - Basu Roy, Upal

AU - Baird, Anne Marie

AU - Ciupek, Andrew

AU - Fox, Jesme

AU - Manley, Eugene

AU - Norris, XX, Kim

AU - Scagliotti, Giorgio V.

AU - Wakelee, Heather A.

AU - Mitsudomi, Tetsuya

AU - Clark, Russell C.

AU - Arndt, Renee

AU - Hirsch, Fred R.

AU - Bunn, Paul A.

AU - Smeltzer, Matthew P.

N1 - Funding Information: Disclosure: Dr. Roy has received institutional research funding from AstraZeneca, Eli Lilly, Merck, Blueprint Medicine, Genentech, G1 Therapeutics, Takeda, Bristol-Myers Squibb, and Janssen not related to the current project. Dr. Baird has received institutional support funding from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi, and Takeda not related to the project; has served as consultant for Janssen (honorarium received by organization) and for Roche (Dublin, Ireland). Dr. Ciupek has been consultant for Novartis, GRAIL Inc., and advisory board member for Novartis, Daiichi Sankyo, AstraZeneca, and Foundation Medicine. Dr. Fox has received institutional funding from AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Eli Lilly, Merck, Takeda, and Roche not related to the project and participated in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Novartis, Debiopharm, and Takeda. Dr. Scagliotti received honoraria from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Johnson & Johnson, Takeda; consulting or advisory role for Eli Lilly, BeiGene, and AstraZeneca; received institutional research funding from Eli Lilly and Merck Sharp & Dohme; and received travel, accommodations from Bayer, all not related to the current project. Dr. Mitsudomi received advisory/lecture fees from AstraZeneca, Novartis, Chugai, Boehringer Ingelheim, Pfizer, Roche, Merck Sharp & Dohme, Thermo Fisher, Roche diagnostics, Bristol-Myers Squibb, Ono Pharmaceutical, Taiho, Takeda, Amgen, Johnson and Johnson, Janssen pharma, Puma, BeiGene, Bridge Biotherapeutics, Eli Lilly, Daiichi Sankyo, and Thermo Fisher; research funding from AstraZeneca, Chugai, Boehringer Ingelheim, Pfizer, Taiho, Ono Pharmaceutical, Merck Sharp & Dohme, Daiichi Sankyo, Eli Lilly, Ethicon, and Bridge Biotherapeutics not related to this project. Dr. Bunn has received consulting income from AstraZeneca, Ascentage, Bristol-Myers Squibb, C-Stone, Imidex, Merck, and Verastem not related to this project. Dr. Smeltzer has worked as a paid research consultant for the Association of Community Cancer Centers. The remaining authors declare no conflict of interest.

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85123063349

U2 - 10.1016/j.jtocrr.2021.100269

DO - 10.1016/j.jtocrr.2021.100269

M3 - Comment/debate

AN - SCOPUS:85123063349

SN - 2666-3643

VL - 3

JO - JTO Clinical and Research Reports

JF - JTO Clinical and Research Reports

IS - 2

M1 - 100269

ER -